Switch theme
Sign up to access all valuation multiples
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
1996
3.0K+
LTM Revenue $2.9B
LTM EBITDA $680M
$10.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Biomarin Pharmaceutical has a last 12-month revenue of $2.9B and a last 12-month EBITDA of $680M.
In the most recent fiscal year, Biomarin Pharmaceutical achieved revenue of $2.9B and an EBITDA of $651M.
Biomarin Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biomarin Pharmaceutical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.4B | $2.9B | XXX | XXX | XXX |
| Gross Profit | $1.6B | $1.9B | XXX | XXX | XXX |
| Gross Margin | 67% | 67% | XXX | XXX | XXX |
| EBITDA | $310M | $651M | XXX | XXX | XXX |
| EBITDA Margin | 13% | 23% | XXX | XXX | XXX |
| Net Profit | $142M | $168M | XXX | XXX | XXX |
| Net Margin | 6% | 6% | XXX | XXX | XXX |
| Net Debt | $358M | $332M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Biomarin Pharmaceutical's stock price is $60.
Biomarin Pharmaceutical has current market cap of $11.4B, and EV of $10.9B.
See Biomarin Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.9B | $11.4B | XXX | XXX | XXX | XXX | $2.49 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Biomarin Pharmaceutical has market cap of $11.4B and EV of $10.9B.
Biomarin Pharmaceutical's trades at 3.7x LTM EV/Revenue multiple, and 16.0x LTM EBITDA.
Analysts estimate Biomarin Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Biomarin Pharmaceutical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $10.9B | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | XXX | XXX |
| EV/EBITDA | 16.8x | XXX | XXX | XXX |
| P/E | 26.8x | XXX | XXX | XXX |
| P/E/Growth | 0.7x | XXX | XXX | XXX |
| EV/FCF | 22.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBiomarin Pharmaceutical's NTM/LTM revenue growth is 10%
Biomarin Pharmaceutical's revenue per employee for the last fiscal year averaged $0.9M, while opex per employee averaged $0.6M for the same period.
Over next 12 months, Biomarin Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Biomarin Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Biomarin Pharmaceutical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 110% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 33% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.9M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 17% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 19% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 26% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 63% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biomarin Pharmaceutical acquired XXX companies to date.
Last acquisition by Biomarin Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Biomarin Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Biomarin Pharmaceutical founded? | Biomarin Pharmaceutical was founded in 1996. |
| Where is Biomarin Pharmaceutical headquartered? | Biomarin Pharmaceutical is headquartered in United States of America. |
| How many employees does Biomarin Pharmaceutical have? | As of today, Biomarin Pharmaceutical has 3.0K+ employees. |
| Who is the CEO of Biomarin Pharmaceutical? | Biomarin Pharmaceutical's CEO is Mr. Alexander Hardy. |
| Is Biomarin Pharmaceutical publicy listed? | Yes, Biomarin Pharmaceutical is a public company listed on NAS. |
| What is the stock symbol of Biomarin Pharmaceutical? | Biomarin Pharmaceutical trades under BMRN ticker. |
| When did Biomarin Pharmaceutical go public? | Biomarin Pharmaceutical went public in 1999. |
| Who are competitors of Biomarin Pharmaceutical? | Similar companies to Biomarin Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Biomarin Pharmaceutical? | Biomarin Pharmaceutical's current market cap is $11.4B |
| What is the current revenue of Biomarin Pharmaceutical? | Biomarin Pharmaceutical's last 12-month revenue is $2.9B. |
| What is the current EBITDA of Biomarin Pharmaceutical? | Biomarin Pharmaceutical's last 12-month EBITDA is $680M. |
| What is the current EV/Revenue multiple of Biomarin Pharmaceutical? | Current revenue multiple of Biomarin Pharmaceutical is 3.7x. |
| What is the current EV/EBITDA multiple of Biomarin Pharmaceutical? | Current EBITDA multiple of Biomarin Pharmaceutical is 16.0x. |
| What is the current revenue growth of Biomarin Pharmaceutical? | Biomarin Pharmaceutical revenue growth between 2023 and 2024 was 18%. |
| Is Biomarin Pharmaceutical profitable? | Yes, Biomarin Pharmaceutical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
